Clinical trial NCT03814486: Retrospective Descriptive Study of Platelet Transfusion in Patients With Palliative Hematologic Malignancies at the University Hospital of Besançon
Official title: Etude Descriptive Retrospective de la Transfusion Plaquettaire Chez Des Patients Atteints d'hémopathie Maligne en Phase Palliative et Suivis au CHU de Besançon
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Platelet Transfusion
Palliative Care
Keywords: platelet transfusion
palliative care
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2019-01-24
Enrollment: 119
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patient with hematological malignancies,transfused in platelet at least once in the last 6 months of life, hospitalised or follow up at the CHU of Besancon at least once and dead during the period of the study

Brief summary: Development of palliative care is less effective for patients with hematologic malignancies. Limited data is available for end of life care in this population, moreover with thrombocytopenic patients. Thrombopenia is a frequent complication, specific of bone marrow involvement in those diseases or its treatments. Yet, a few studies was interested in, whereas platelet transfusion is the only treatment indicated. As it represent a scarce, limited resource, the ethical principles are in conflict in this setting.

The purpose of this study was to describe retrospectively platelet transfusion in the six last few month of life of patients with hematologic malignancies at the CHU of Besançon (France) between 01/07/15 and 31/12/16.


Eligibility criteria: Inclusion Criteria:

* patient with hematological malignancies
* transfused in platelet at least once in the last 6 months of life
* hospitalised or follow up at the CHU of Besancon at least once
* dead during the period of the study

Exclusion Criteria:

* patient with other oncologic malignancies
* not transfused in platelet in the last 6 months of life
* never hospitalised or follow up at the CHU of Besancon
* alive

Primary outcomes:
measure: evaluate frequency of platelet transfusion at the end of life
timeFrame: 18 months (between 07/01/2015 and 12/31/2016)
measure: evaluate efficacy of prophylactic platelet transfusion at the end of life
timeFrame: 18 months (between 07/01/2015 and 12/31/2016)
measure: evaluate efficacy of non prophylactic platelet transfusion at the end of life
timeFrame: 18 month (between 07/01/2015 and 12/31/2016)
Secondary outcomes:
measure: demographic characteristic
timeFrame: 18 months (between 07/01/2015 and 12/31/2016)
Other outcomes:
Locations:
city: Besançon
country: France
facility: Moracchini
Study officials:
affiliation: Centre Hospitalier Universitaire de Besancon
name: regis aubry, ph
role: STUDY_DIRECTOR
References:
citation: Hochsmann B, Moicean A, Risitano A, Ljungman P, Schrezenmeier H. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant. 2013 Feb;48(2):168-73. doi: 10.1038/bmt.2012.220. Epub 2012 Dec 3.
citation: Sherbeck JP, Boss RD. Ethical Questions about Platelet Transfusions at the End of Life. AMA J Ethics. 2016 Aug 1;18(8):764-70. doi: 10.1001/journalofethics.2016.18.8.ecas1-1608.
citation: Salacz ME, Lankiewicz MW, Weissman DE. Management of thrombocytopenia in bone marrow failure: a review. J Palliat Med. 2007 Feb;10(1):236-44. doi: 10.1089/jpm.2006.0126.
citation: Lassauniere JM, Bertolino M, Hunault M, Zittoun R, Verspieren P, Moh-Klaren J, Jaulmes D, Colombat P. Platelet transfusions in advanced hematological malignancies: a position paper. J Palliat Care. 1996 Spring;12(1):38-41.
citation: Boggs DR. Jehovah's Witnesses with leukemia. Hosp Pract (Off Ed). 1985 Mar 15;20(3):92, 94-5, 98 passim. doi: 10.1080/21548331.1985.11703015. No abstract available.
citation: Wang WS, Ma JD, Nelson SH, Revta C, Buckholz GT, Mulroney C, Roeland EJ. Transfusion practices at end of life for hematopoietic stem cell transplant patients. Support Care Cancer. 2018 Jun;26(6):1927-1931. doi: 10.1007/s00520-017-4023-y. Epub 2017 Dec 28.